

DATED _____ **200**

- (1) THE WELLCOME TRUST LIMITED**
- (2) [COMPANY] LIMITED**
- (3) [FOUNDER NAME]**

COMPANY FUNDING AGREEMENT (SDDI)

Bird & Bird
90 Fetter Lane
London EC4A 1JP
Tel: 020 7 415 6000
Fax: 020 7 415 6111

Ref: NKM/CMF/WELTR.0002

CONFIDENTIAL.

THIS AGREEMENT is made and entered into as of the [] day of [] 20

BETWEEN:

- (1) **THE WELLCOME TRUST LIMITED** a company registered in England under number 2711000 whose registered office is at 215 Euston Road, London NW1 2BE, as Trustee of the Wellcome Trust, a charity registered in England under number 210183, (the “**Trust**”); and
- (2) [] **LIMITED** a company registered in [England and Wales/Scotland] under number [] whose registered office is [Address] (the “**Company**”); and
- (3) [] of [Address] (the “**Founder**”).

RECITALS:

- (A) The Company is a company incorporated on [Date] in [England/Scotland] under the provisions of the Companies Act 1985, as a private company limited by shares, details of which are set out in Schedule 3.
- (B) At the date of this Agreement, the Company has an authorised share capital of [£•] divided into [•] Ordinary Shares of £[•] each, of which [•] Ordinary Shares have been issued fully paid and registered in the name[s] of the person[s] listed in Schedule 3.
- (C) In order to further its charitable objects, the Trust wishes to make a Programme Related Investment (PRI) by way of an unsecured convertible loan of a maximum amount of [• Sterling Pounds (£•)] to the Company to progress [*insert description of healthcare benefit*]

1. INTERPRETATION

In this Agreement, unless the context otherwise requires:

- 1.1 “**Accounts Date**” means [date];
- 1.2 “**Accrued Interest**” means interest payable and accrued in respect of the Loan as calculated in accordance with Clause [3.2];
- 1.3 “**Advance**” means the borrowing of the Facility by drawdown by the Company from time to time in accordance with Clause [2.6];
- 1.4 “**Affiliate**” means, with respect to a given entity, any person, corporation, partnership or other entity, that Controls, is Controlled by, or is under common Control with such entity;
- 1.5 “**Agreement**” means this agreement as may be amended in accordance with the provisions of this agreement;
- 1.6 “**Anniversary Date**” means each anniversary of the Effective Date of this Agreement or, if such date is not a Business Day, the

next following Business Day;

- 1.7 **“Audited Accounts”** means the audited balance sheet of the Company as at the end of the relevant financial year of the Company and the audited profit and loss account of the Company for the relevant financial year of the Company, together with the related cash flow statements, notes, directors’ reports and Auditors’ reports (unless statutory requirements dictate the accounts do not need to be audited, in which case the accounts shall be those approved by the Company’s accountants);
- 1.8 **“Auditors”** means [Name of Auditors] or such other firm of Chartered Accountants as may be appointed as auditors of the Company from time to time;
- 1.9 **“Background IPRs”** means any IPRs created, devised, generated, owned by or licensed to the Company or which the Company has rights to prior to the Effective Date, which are necessary or useful for the protection or exploitation of the Project IPRs or the Project Patents;
- 1.10 **“Board”** means the board of directors of the Company from time to time;
- 1.11 **“Business Day”** means a day on which banks are normally open for business and which is not a Saturday or Sunday or a bank or public holiday in [Scotland or England and Wales];
- 1.12 **“Business IPRs”** means the IPRs used or required by the Company in the operation of its business;
- 1.13 **“Business Plan”** means the Company’s business plan dated [date];
- 1.14 **“BVCA”** means the British Venture Capital Association or an overseas body equivalent to it;
- 1.15 **“Change of Control”** means, in relation to the Company, where a person (or persons acting in concert) directly or indirectly, including through any Subsidiary or Holding Company or Subsidiary of such Holding Company:
- (a) has beneficial ownership over more than 50 per cent of the total voting rights conferred by all the issued shares in the capital of the Company which are ordinarily exercisable in general meeting; or
 - (b) has the right to appoint or remove a majority of its directors; or
 - (c) has power to direct that the affairs of

CONFIDENTIAL. SUBJECT TO CONTRACT.

the Company are conducted in accordance with its wishes,

in each case where such person or persons did not have such beneficial ownership, right or power at the Effective Date;

- 1.16 **“Claim”** means any claim by the Trust for breach of any of the Warranties;
- 1.17 **“Companies Acts”** means Companies Act 1985, Companies Act 1989, Business Names Act 1985 and Enterprise Act 2002;
- 1.18 **“Conditions”** means the satisfaction by the Company (to the reasonable satisfaction of the Trust) of the Conditions described in Schedule 7;
- 1.19 **“Connected Persons”** means a person connected with the Company or any director or any former director or any shareholder of the Company within the meaning of Section 839, Income and Corporation Taxes Act 1988;
- 1.20 **“Control”** means the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of an entity, or the right to receive more than fifty percent (50%) of the profits or earnings of an entity. Any other relationship which in fact results in one entity having a decisive influence over the management, business and affairs of an other entity shall also be deemed to constitute Control;
- 1.21 **“Conversion Price”** means:
- (i) ¹ [in the case of conversion pursuant to Clause 4.1.1.1, a price per share of £●; or]

[in the case of conversion pursuant to Clause 4.1.1.1, a price per share which is at a discount of 20% to the share price at the next fund raising led by a member of the BVCA after the Effective Date; or]
 - (ii) in the case of a Listing under Clause 4.1.1.3, a price per share which is at a discount of 20% to the share price upon Listing; or
 - (iii) in the case of a Sale under Clause 4.1.1.2, a price per share which is at a discount of 20% to either the price per share at which the

¹ Price per share to be agreed up front where possible based on one of the following options: 1) the price per share at the last professional investment round or 2) a 20% discount to the price per share at the next professional funding round.

CONFIDENTIAL. SUBJECT TO CONTRACT.

acquirer purchased the shares of the Company, or the total price paid for the business and undertaking of the Company and its subsidiaries divided by the number of shares then issued (as the case may be).

- 1.22 **“Disclosure Letter”** means the disclosure letter dated the same date as this Agreement and as subsequently amended and agreed by the Parties on each Anniversary Date and on the date of each Advance;
- 1.23 **“Drawdown Date”** means a Business Day on which an Advance is made available to the Company;
- 1.24 **“Drawdown Notice”** means a notice as detailed in Schedules 1 or 2 of this Agreement;
- 1.25 **“Drawdown Period”** means the period starting on the date of this Agreement and ending on the date which is the earlier of the Repayment Date or [48] months from the date of this Agreement;
- 1.26 **“Effective Date”** means the date of this Agreement as set out at the top of page 1 of this Agreement;
- 1.27 **“Encumbrance”** means any claim, charge, mortgage, security, lien, option, equity, power of sale, hypothecation or other third party rights, retention of title, right of pre-emption, right of first refusal or security interest of any kind;
- 1.28 **“Event of Default”** means any event or circumstance more particularly described in Clause 10;
- 1.29 **“Equity Holding”** means any equity or any other interest (whether by way of debenture, warrant, security or otherwise) from in any third party company transferred or issued in consideration of the assignment or grant of a licence or an option thereto to such third party company in respect of any Project Patents and/or Project IPRs;
- 1.30 **“Facility”** means the loan facility made available by the Trust to the Company on the terms and conditions of this Agreement;
- 1.31 **“Facility Amount”** means the amount of the Facility as set out in Clause [2.2];
- 1.32 **“Gross Revenues”** means in any Year after the Effective Date all income received by the Company during that Year excluding all equity investment or money paid by way of a grant;
- 1.33 **“Group”** means, in relation to any Party, its Holding

CONFIDENTIAL. SUBJECT TO CONTRACT.

Companies, its Subsidiaries and the Subsidiaries of those Holding Companies;

- 1.34 **“Holding Company”** shall be construed in accordance with s736 Companies Act 1985 as amended;
- 1.35 **“IPRs”** means (i) patents, designs, trade marks and trade names (whether registered or unregistered), copyright and related rights, database rights, know-how and confidential information; (ii) all other intellectual property rights and similar or equivalent rights anywhere in the world which currently exist or are recognised in the future; and (iii) applications, extensions and renewals in relation to any such rights;
- 1.36 **“Licensed-In IPRs”** means all IPRs of a third party which are or have been used by the Company under the terms of any agreement, arrangement or understanding (including software licences) under which a third party permits the Company to use IPRs;
- 1.37 **“Listing”** means the admission of the equity share capital of the Company, or any part of it, to trading on the Official List of the London Stock Exchange, AIM, NASDAQ, the New York Stock Exchange, The American Stock Exchange or to any other Recognised Investment Exchange;
- 1.38 **“Loan”** means the aggregate principal amount of the Facility from time to time borrowed and outstanding under this Agreement;
- 1.39 **“Management Accounts”** means the unaudited monthly management accounts of the Company for the period ending ●;
- 1.40 **“Milestone One”** means the achievement by the Company (to the reasonable satisfaction of the Trust) of Milestone One as described in Schedule 7;
- 1.41 **“Milestone Two”** means the achievement by the Company (to the reasonable satisfaction of the Trust) of Milestone Two as described in Schedule 7;
- 1.42 **“Milestone Three”** means the achievement by the Company (to the reasonable satisfaction of the Trust) of Milestone Three as described in Schedule 7;
- 1.43 **“Milestones”** means Milestone One, Milestone Two and Milestone Three;
- 1.44 **“Net Revenues”** means in any Year after the Effective Date Gross Revenues less the amount of annual Operating Costs in any Year;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 1.45 **“Observer”** means a person entitled to receive notice of, attend and speak (but not vote) at all meetings of the Board and committees of the Board.
- 1.46 **“Operating Costs”** means salaries, rental payable on real property leases and licences, operational and manufacturing costs, patent costs, payments made to advisors (including lawyers, accountants, patent attorneys and bona fide consultants), utilities, IT support, equipment, asset leasing and hire purchase arrangements (excluding company cars), consumables, cost of equipment; sub-contractors directly related to the business of the Company and such other items as may be agreed by the Trust but for the avoidance of doubt shall exclude capital expenditure, depreciation, interest payments to licensees of intellectual property, taxes and fines;
- 1.47 **“Ordinary Shares”** means the ordinary shares of [£1] each in the capital of the Company from time to time;
- 1.48 **“Parties”** means the parties to this Agreement, or any of them, as the context may require and **“Party”** shall be interpreted accordingly;
- 1.49 **“Principal Investigator”** means [name of Principal Investigator];
- 1.50 **“Project Advisory Group”** means the group constituted in accordance with Clause 13;
- 1.51 **“Project Compound”** means any compound in respect of which activities are undertaken by the Company in the course of the Research, and shall include the chemical compound as well as all esters, salts, hydrates, solvates, polymorphs and isomers thereof, and shall include compositions comprising such compound, or esters, salts, hydrates, solvates, polymorphs, isomers and enantiomers;
- 1.52 **“Project Inventions”** means any inventions created, devised or arising out of the Company’s undertaking and performance of the Research;
- 1.53 **“Project IPRs”** means any IPRs (including the Project Patents) created, devised or arising out of the Company’s undertaking and performance of the Research or any part of it;
- 1.54 **“Project Patents”** means any patent applications that may be made by the Company which claim any Project Inventions or parts thereof, and any patents resulting from any such applications, utility certificates, improvement patents and models and certificates of addition and all foreign counterparts of them in all countries,

including any divisional applications and patents, refiling, renewals, continuations, continuations-in-part, patents of addition, extensions, (including patent term extensions,) reissues, substitutions, confirmations, registrations, re validations, pipeline and administrative protections and additions, and any equivalents of the foregoing in any and all countries of or to any of them, as well as any supplementary protection certificates and equivalent protection rights in respect of any of them;

- 1.55 **“Project Revenues”** means any cash sums, other monetary consideration or equity actually received by the Company from time to time in respect of its exploitation of Project IPRs, including the assignment or grant to any other person of a licence or an option thereto in respect of any Project IPRs, whether by way of royalties, licences fees or otherwise; for the avoidance of doubt Project Revenues shall include consideration received by way of royalties, signature fees, milestone payments, the provision of premises or equipment or payment in the form of equity but shall not include any equity investment made in the Company by a third party or money paid to the Company by way of a grant. Where such consideration is received other than in money the value of the consideration shall be determined by reference to the value of the goods, services, licence or other benefit to the Company;
- 1.56 **“Recognised Investment Exchange”** has the meaning given to it in Section 285 of the Financial Services and Markets Act 2000;
- 1.57 **“Repayment Date”** means the earlier of the date on which an Event of Default first occurs, and the date which is five (5) Business Days following the date of any notice served by the Trust on the Company pursuant to Clause 4;
- 1.58 **“Research”** means the research activities described in the application a copy of which is set out in Schedule 5, as may be amended by written agreement between the Parties from time to time;
- 1.59 **“Research Programme”** means the detailed plan for carrying out the Research a copy of which is set out in Schedule 6, as may be amended by written agreement between the Parties from time to time;
- 1.60 **“Sale”** means (i) the acquisition by any person of 51 *per cent* of the shares of the Company or all of the shares not already owned by the acquirer; or (ii) the acquisition by any person of the whole or substantially the whole of the business and undertaking of the Company and its subsidiaries;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 1.61 **“Subsidiary”** shall be construed in accordance with s736 Companies Act 1985 as amended;
- 1.62 **“Tax”** means all forms of taxation, duties, imposts, levies and rates whenever created or imposed and whether of the United Kingdom or elsewhere and all penalties and interest payable in respect thereof;
- 1.63 **“Trust Direct Costs”** means any costs and expenses incurred or allowed from time to time in accordance with this Agreement by or for the account of the Trust under Clause 16 in marketing the Project IPRs and negotiating, concluding or enforcing agreements for the licensing or other exploitation of the same (including by way of acquisition of equity in a company), including without limitation:
- all reasonable legal, accounting and other professional fees and charges;
 - all costs associated with transferring entitlements to Equity Holdings to transferees;
 - official filing, prosecution, maintenance and renewal fees; and
 - (d) travelling and other out-of-pocket expenditure.
- 1.64 **“Warranties”** means the representations and warranties contained in Clause 6 and Schedule 4 and each and any of them;
- 1.65 **“Warrantors”** means the Founder[s], [*add any other members of the management team*] and the Company; and
- 1.66 **“Year”** means a period of 12 months starting on the Repayment Date or the Effective Date as the case may require and ending on the date 12 months thereafter and each subsequent period of 12 months.
- 1.67 References in this Agreement to any statutory provisions shall be construed as references to those provisions as respectively amended consolidated or re-enacted (whether before or after the Effective Date) from time to time and shall include any provisions of which they are consolidations or re-enactments (whether with or without amendment).
- 1.68 The Schedules and Recitals form part of this Agreement and any reference to this Agreement shall include the Schedules and Recitals.
- 1.69 In this Agreement:

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 1.69.1 the masculine gender shall include the feminine and neuter and the singular number shall include the plural and vice versa;
- 1.69.2 references to persons shall include bodies corporate, unincorporated associations, partnerships and individuals;
- 1.69.3 except where the contrary is stated, any reference in this Agreement to a Clause or Schedule is to a Clause of or Schedule to this Agreement, and any reference within a Clause or Schedule to a sub-Clause, paragraph or other sub-division is a reference to such sub-Clause, paragraph or other sub-division so numbered or lettered in that Clause or Schedule.
- 1.70 The headings in this Agreement are inserted for convenience only and shall not affect the construction of the provision to which they relate.
- 1.71 References to the winding-up of a person include the amalgamation, reconstruction, reorganisation, administration, dissolution, liquidation, bankruptcy, merger or consolidation of such person and an equivalent or analogous procedure under the law of any jurisdiction in which that person is incorporated, domiciled or resident or carries on business or has assets.
- 1.72 Any reference to books, records or other information includes books, records or other information in any format or medium including paper, electronically stored data, video or audio recordings and microfilm.
- 1.73 Any phrase introduced by the terms "including", "include", "in particular" or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms
- 1.74 Where reference is made in this Agreement to the prior written consent of the Trust being required in respect of any matter, the Company shall give not less than twenty (20) Business Days notice to the Trust of the matter for which such consent is required.

2. LOAN TO BE ADVANCED BY THE TRUST

- 2.1 In consideration of the rights and obligations of the Parties as set out in this Agreement, the Trust shall grant the Facility to the Company on the terms and conditions set out in this Agreement.
- 2.2 The maximum principal amount of the Facility shall be [● Pounds Sterling (£●)].
- 2.3 The Loan shall be used by the Company for the sole purpose of providing funding and support for the Research and shall be used for no other purpose without the prior written consent of the Trust.
- 2.4 The Company shall repay the Loan and any Accrued Interest at the earlier of:
- (i) the first occurrence of an Event of Default;
 - (ii) if the Trust decides to implement the option set out in Clause 4.1.2, no later than the Repayment Date.

CONFIDENTIAL. SUBJECT TO CONTRACT.

2.5 The first tranche of the Facility may be drawn down by the Company at any time after the Effective Date by providing to the Trust a Drawdown Notice in the form set out in Schedule 1. Within 20 Business Days of the date of receipt by the Trust of such Drawdown Notice (subject to the satisfaction of the conditions set out in Clause 2.9), the Company shall draw down the Facility in respect of [• Pounds Sterling (£•).] The obligations under Clauses 3, 4, 5, 6, 7 and 11 shall not come into effect unless and until such notice is submitted.

2.6 When the Company considers that each of Milestone [One] and Milestone [Two] have been achieved:

2.6.1 The Company shall as soon as reasonably practicable serve a signed Milestone Certification and Drawdown Notice on the Trust in the form set out in Schedule 2; and

2.6.2 The Trust shall confirm to the Company in writing, within 20 Business Days of receipt by the Trust of notification pursuant to Clause 2.6.1 either that:

- (i) the Milestone has been achieved to the Trust's reasonable satisfaction and drawdown of the next tranche of funds may take place, in which case, within 20 Business Days of the date of receipt by the Company of the Trust's confirmation pursuant to this paragraph (i), the Company shall draw down the Facility in the amounts set out below:

| Tranche | Amount of Advance | Payable on Achievement of: |
|---------|-------------------|----------------------------|
| [2 | £ • | Milestone One] |
| [3 | £ • | Milestone Two] |

2.6.3 the Milestone has not been achieved to the Trust's reasonable satisfaction and that the drawdown may not take place, in which case it shall provide the Company with reasonable details of the grounds on which it has reached this decision. The Trust may, at its sole discretion, grant the Company a reasonable period of time ("Milestone Extension"), in order to address the reasons why the Trust has judged that a particular Milestone has not been met. Upon the expiry of a Milestone Extension, the Trust shall, at its sole discretion, decide whether or not to permit payment of the relevant tranche of funding to the Company.

2.7 If any Milestones have not been achieved by the last day of the Drawdown Period, the Facility shall be cancelled to the extent not borrowed, unless agreed otherwise in writing by the Trust. The Company and the Founder[s] undertake to use their best efforts to ensure that the Conditions will be satisfied at all times throughout the duration of the Research and that Milestone [Three] will be achieved by the date specified in Schedule 7.

2.8 The Founder[s] hereby confirm[s] that the Company shall have full power and authority to draw down the Facility and that no further consent of the Founder[s] shall be required.

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 2.9 The Trust will only be obliged to make an Advance if on the date of the Drawdown Notice and on the proposed Drawdown Date:
- (i) no Event of Default is subsisting or would result from the proposed Advance;
 - (ii) the Warranties are true and correct in all respects, subject to the matters set out in the Disclosure Letter;
 - (iii) the contents of the Disclosure Letter are reasonably acceptable to the Trust;
 - (iv) no notice has been issued by the Trust pursuant to Clause 4.1, and
 - (v) the Trust has provided confirmation to the Company in accordance with Clause 2.6.2 that the relevant Milestone has been met.
- 2.10 The Company may, if it gives the Trust not less than thirty (30) days prior written notice, repay the whole of the Loan together with Accrued Interest in cash at any time, provided that during such notice period prior to the repayment of the Loan the Trust shall be entitled to exercise its option pursuant to Clause 4.1.1.1.
- 2.11 All payments made by the Company to the Trust or by the Trust to the Company as the case may be under this Agreement shall be made in Pounds Sterling. Payment shall be made by electronic wire transfer of immediately available funds directly to the account of the relevant Party designated below or to any other account which the relevant Party may specify by written notice.

Bank Account for Company:

Account Name: []
Account No.: []
Bank: []
Sort code: []
SWIFT code: []
Branch: []

Bank Account for The Wellcome Trust:

Account Name: The Wellcome Trust
Account No.: 40856673
Bank: HSBC Bank plc
Sort code: 40-03-28
SWIFT code: MIDLGB21
Branch: 31 Holborn Circus EC1N 2HR

- 2.12 Written confirmation of such transfer shall be sent by the Party sending the funds to the individual at the Party receiving the funds at the address provided in clause 22.1.
- 2.13 Each of the Trust and the Company shall pay any and all taxes levied in respect of all payments it receives or makes under this Agreement. Any withholding or other taxes that either Party is required by law to withhold or pay on behalf of the other Party, with respect to any payments to it under this Agreement, shall be deducted from such payments and paid

CONFIDENTIAL. SUBJECT TO CONTRACT.

contemporaneously with the remittance to the other Party, together with evidence of such withholding or payment. Such withholding and payment shall fully discharge the Party making the payment and no further payment shall be required by the payor to the payee. The Party withholding or making such payment shall furnish the other Party with appropriate documents to secure application of the most favourable rate of withholding tax under applicable law.

- 2.14 The Company undertakes not to seek, apply for or accept (whether by way of loan, grant or any other funding arrangement) without the Trust's prior written consent (such consent not to be unreasonably withheld) any other funding or support (whether in kind or otherwise) for the Research, whether commercial or non-commercial, for the duration of the Research.

3. INTEREST

- 3.1 If the Trust elects that the Company shall repay the Loan pursuant to Clause 4.1.2, Accrued Interest shall be added to the amount of the Loan which is to be repaid on the relevant Repayment Date as set out in clause 3.2 below. If the Trust elects that the Company shall repay the Loan in part pursuant to Clause 4.1.2, a pro-rata proportion of the Accrued Interest shall be added to the amount of the Loan that is to be repaid on the relevant Repayment Date.

- 3.2 If the Trust elects that the Company shall repay the Loan, interest shall be deemed to have accrued on a daily basis on the amount of the Loan from time to time outstanding at the rate of two per cent (2%) per annum above NatWest Bank plc base rate from time to time. Such interest shall have accrued from day to day by reference to a year of three hundred and sixty five (365) days and such interest shall be deemed to have been added to the principal amount of the Loan annually on each Anniversary Date and on each Repayment Date (if the relevant Repayment Date is not an Anniversary Date).

- 3.3 If the Company fails to pay any amount payable by it under this Agreement on the relevant due date, interest shall accrue on the overdue amount from the due date up to the date of actual payment (both before and after judgement) at a rate which is the sum of three per cent per annum (3%) and the rate which would have been payable if the overdue amount had constituted a loan in an amount equal to such overdue amount. Any interest accruing under this Clause 3.3 shall be immediately payable by the Company on demand.

4. CONVERSION OR REPAYMENT OPTION

- 4.1 The Trust may, in its absolute discretion, serve a written demand on the Company requiring that the Company:

- 4.1.1 convert the full amount or part only of the Loan into fully paid new Ordinary Shares in accordance with clause 4 in the following circumstances:

4.1.1.1 at any time upon request by the Trust; or

4.1.1.2 in the case of a Sale, immediately prior to the completion of a Sale; or

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 4.1.1.3 in the case of a Listing, immediately prior to admission to trading of the shares in the Company on the Recognised Investment Exchange,
 - 4.1.2 repay the full amount or part only of the Loan together with Accrued Interest in accordance with clause 4 in the following circumstances:
 - 4.1.2.1 at any time after the third anniversary of the Effective Date in accordance with Clause 4.4; or
 - 4.1.2.2 in the case of a Sale, immediately prior to the completion of a Sale; or
 - 4.1.2.3 in the case of a Listing, immediately prior to admission to trading of the shares in the Company on the Recognised Investment Exchange,
 - 4.1.3 pay a share of Project Revenues to the Trust in accordance with Clause 5.
- 4.2 The Trust may not require the Company to repay the Loan and Accrued Interest pursuant to Clause 4.1.2 if, as a result of such repayment, the Company is reasonably likely to become insolvent provided that the Trust shall be permitted to either elect for conversion of the Loan to be made pursuant to Clause 4.1.1 or, without prejudice to the Trust's right to demand repayment at a future time, to withdraw a demand for repayment under this Clause 4.1 if, following service of the demand by the Trust, it is determined in the reasonable opinion of the Board based on the most recent management accounts of the Company or other appropriate evidence that the Company is reasonably likely to become insolvent. For the purposes of this Clause the Company shall be considered to be insolvent if, following the repayment, it would be unable to pay its debts as they fall due.
- 4.3 Any written demand served by the Trust on the Company shall state the amount of the Loan and Accrued Interest that shall be repaid (the "**Repayment Amount**") and shall specify that part of the Loan (if any) that shall be converted into Ordinary Shares (the "**Conversion Amount**"). For the avoidance of doubt the Trust may in its absolute discretion require the repayment of the Loan (and Accrued Interest) part in cash and part by the conversion into Ordinary Shares. Accrued Interest shall only be repayable in cash.
- 4.4 If the Trust decides to implement the option set out in Clause 4.1.2.1 the Repayment Amount shall be due and payable (with the first payment being due on the Repayment Date) as set out below:
 - 4.4.1 on the Repayment Date the Company shall pay to the Trust an amount equal to twenty per cent (20%) of the Net Revenues of the Company received by it during the Year immediately preceding the Repayment Date (provided it does not exceed the Repayment Amount) and, subject to Clause 4.4.2 below thereafter, on each subsequent anniversary of the Repayment Date an amount equal to

CONFIDENTIAL. SUBJECT TO CONTRACT.

twenty per cent (20%) of the Net Revenues of the Company received during the Year immediately preceding that anniversary until the Repayment Amount has been paid in full;

- 4.4.2 if the Repayment Amount has not been repaid in full pursuant to Clause 4.1 or Clause 4.4.1 by the date seven years from the Effective Date (the “**Cut-Off Date**”), the Company shall (in lieu of making any payments under clause 4.4.1 above) on the first anniversary of the Repayment Date following the Cut-Off Date pay the Trust an amount equal to twenty per cent (20%) of the Gross Revenues of the Company received by it during the Year immediately preceding that anniversary and on each subsequent anniversary of the Repayment Date an amount equal to twenty per cent (20%) of the Gross Revenues of the Company received during the Year immediately preceding that anniversary until the Repayment Amount has been repaid in full.

For the avoidance of doubt at any time until the Repayment Amount has been repaid in full the Trust shall be entitled to convert the Loan (or any balance outstanding) into Ordinary Shares pursuant to Clause 4.1.1.

- 4.5 If the Trust decides to implement the option set out in Clause 4.1.1, the Conversion Amount shall be converted into such number of fully paid new Ordinary Shares as, at the Conversion Price, have an aggregate value equal to the Conversion Amount (as nearly as practicable, ignoring fractions and rounding down to the nearest whole number of Ordinary Shares). On the relevant Repayment Date the Company shall issue the appropriate number of new Ordinary Shares to the Trust and, as soon as practical thereafter (and in any event no later than twenty (20) Business Days following the relevant Repayment Date), shall enter the Trust as a member in its register of members and shall send a share certificate to the Trust at its address set out in Clause 22.1.
- 4.6 The Company undertakes at all times to ensure that it has sufficient authorised but unissued share capital and has obtained all necessary shareholders consents and approvals as may be required to issue the Ordinary Shares to the Trust pursuant to this Clause 4.
- 4.7 If, while the Loan is capable of being converted into Ordinary Shares, the Company shall make:
- 4.7.1 an issue of shares by way of capitalisation of profits or reserves (including any share premium account or capital redemption reserve to the holders of Ordinary Shares); or
- 4.7.2 a sub-division or consolidation of Ordinary Shares; or
- 4.7.3 a distribution in specie; or
- 4.7.4 a repayment, return or distribution of capital (including a distribution of capital profits (whether realised or not) or capital reserves); or
- 4.7.5 if any event similar to those described in Clauses 4.7.1 to 4.7.4 shall occur,

CONFIDENTIAL. SUBJECT TO CONTRACT.

then the Conversion Price shall be adjusted in such manner as the Auditors shall certify. In the event that the Trust or the Company is not satisfied with any certificate of the Auditors issued pursuant to this Clause 4.7 for any reason in any circumstance in which such certificate is issued and so notifies the other Party and the Auditors in writing within 14 days of receiving such certificate or learning of its contents (if a copy of such certificate is not sent to him), the matter shall be submitted as soon as practicable to an independent firm of chartered accountants. Such firm of chartered accountants shall be agreed between the Trust and the Board of the Company or in default of agreement as nominated by the President for the time being of the Institute of Chartered Accountants of England and Wales, such firm of chartered accountants to be deemed to be an expert (and not an arbiter) and whose decision as to the matter shall be final and binding on all persons save in the case of manifest error. The fees and expenses of the independent firm of chartered accountants shall be borne by such person or persons as reasonably determined by such firm.

- 4.8 The provisions of this Clause 4 are, for the avoidance of doubt, in addition to the provisions of Clause 10 (Events of Default).
- 4.9 If at any time the Company is seeking to obtain funding from third party professional investors who are members of the BVCA, the Trust will discuss with the Company the repayment of the Loan (and Accrued Interest if relevant) pursuant to Clause 4.1 prior to completion of such investment, provided that the Conversion Price shall not be subject to amendment.

5. REVENUE SHARING OPTION

- 5.1 The Trust shall have the option, in its discretion, to notify the Company in writing at any time that it will take a share of Project Revenues and Equity Holdings received by the Company in respect of exploitation of the Project IPRs instead of exercising its right to convert the Loan into Shares under Clause 4.1.1 or require the repayment of the Loan under Clause 4.1.2.
- 5.2 If the Trust exercises its option pursuant to Clause 5.1, aggregate Project Revenues and Equity Holdings shall be shared between the Company and the Trust in the following proportions:
- | | | |
|----|-----------|-------------------------------------|
| a) | Company | [50% (fifty percent)]; and |
| b) | the Trust | [50% (fifty percent)]. ² |

and the Trust shall cease to have the right to convert the Loan into Shares under Clause 4.1.1 or to require repayment of the Loan under Clause 4.1.2.

- 5.3 If, following the end of the Research, the Company (or any third party) contributes any funding to further develop any of the Project Compounds, the share of Project Revenues and Equity Holdings due to the Trust in respect of

² Standard share is 50:50 unless applicant can justify otherwise. The case for re-consideration of the standard share should be made at the time the applicant is notified that the Wellcome Trust wishes to receive a full application for funding.

CONFIDENTIAL. SUBJECT TO CONTRACT.

that Project Compound on the exercise of the Trust's option pursuant to Clause 5.1 shall be reduced by the formula $X/(X+Y)$ where X is the Facility Amount in pounds sterling and Y varies as follows:

- 5.3.1 Where a Project Compound is funded to the pre-clinical stage, Y=£750,000 (seven hundred and fifty thousand pounds sterling);
 - 5.3.2 Where a successful Phase I trial of a Project Compound is funded, Y=£1,750,000 (one million pounds sterling), and
 - 5.3.3 Where a successful Phase II trial of a Project Compound is funded, Y=£6,750,000 (five million pounds sterling)
- 5.4 Where any Project Revenues or Equity Holdings are received by the Company as part of the consideration for the grant of rights which includes rights other than those arising under the Project IPRs, then the consideration shall be apportioned by the Company between, on the one hand, the Project IPRs, and on the other hand, any other rights granted by the Company, in such manner as may be determined by the Auditors to be fair and reasonable. If Project Revenues include consideration other than cash the Company shall pay to the Trust an amount in cash as required to satisfy the Trust's share calculated in accordance with Clause 5.2 unless agreed otherwise between the Parties.

6. **WARRANTIES**

- 6.1 The Company represents and warrants to the Trust and the Founder[s] separately represent[s] and warrant[s] to the Trust that, on the Effective Date, on each Anniversary Date and on the date of any Advance, each of the statements set out in Schedule 4 is true and accurate in all respects (subject to the Disclosure Letter).
- 6.2 The Warrantors severally acknowledge that they have given the Warranties with the intention of inducing the Trust to enter into this Agreement and, as the case may be, to make the Advances on the achievement of each of the Milestones and that the Trust has been induced to enter into this Agreement and make available the Facility on the basis of and in full reliance upon them.
- 6.3 Each of the Warranties shall be construed as a separate and independent warranty and (save where expressly provided to the contrary) shall not be limited or restricted by reference to or inference from any other term of this Agreement or any other Warranty.
- 6.4 The limitations on liability set out in Clause 7 shall apply in respect of the liability of the Warrantors under this Agreement provided that no provision of Clause 7 shall apply to limit or exclude the liability of the Warrantors in circumstances of fraud or wilful concealment by the Warrantors.
- 6.5 Where any statement in the Warranties is qualified by reference to the knowledge, awareness or belief of the Warrantors, the Warrantors shall be deemed to be aware of all matters which they would have known (or its directors would have known) if they had made diligent and careful enquiry.

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 6.6 The Warrantors will immediately cause to be disclosed in writing to the Trust any fact, matters, circumstances or other information which may become known to any of them which is a breach of or can reasonably be expected to be, or be likely to cause, a breach of any of the Warranties.
- 6.7 If any deduction or withholding is required by law to be made from any sum payable by the Founder[s] to the Trust pursuant to any Claim, the Founder[s] shall be obliged to pay to the Trust such sum as will after the deduction or withholding has been made, leave the Trust with the same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding.
- 6.8 If any sum paid to the Trust pursuant to any Claim is or will be chargeable to Tax, the Founder[s] shall be obliged to pay such further sums as will, after payment of the Tax, leave a sum equal to the amount that would otherwise have been payable if Tax had not been so chargeable

7. **AUDIT**

- 7.1 The control of expenditure to be funded under this Agreement must be governed by the normal standards and procedures of the Company and must be covered by the formal audit arrangements that exist in the Company.
- 7.2 The Trust reserves the right to ask for confirmation from the external auditors of the Company that the external auditors have signed their opinion on the annual accounts of the Company without qualification and the management letter from the auditors raises no matters that did or could not significantly affect the administration of awards made by the Trust (at the Trust's expense), if requested.
- 7.3 The Trust reserves the right, at its discretion and expense, to commission an audit of any expenditure of the Facility and any amounts or equity due to the Trust under this Agreement. The Company must provide access to accounting and other records relating to this Agreement for auditors from or appointed by the Trust (at the Trust's expense), if requested. Such access must include the right to verify physically any equipment acquired under the Facility. Where elements of expenditure under this Agreement have been subcontracted, the Company should ensure that the auditor's access extends to the accounts and records of any such subcontractor.

8. **LIMITS ON LIABILITY**

- 8.1 The liability of the Founder[s] under this Agreement shall be limited as follows:
- 8.1.1 the Trust shall not be entitled to recover any damages in respect of any Claim or Claims unless the aggregate loss or damage amount in respect of all such Claim or Claims for which [each of] the Founder[s] is[are] liable exceeds ten thousand Pounds Sterling (£10,000), in which event a claim in respect of the total loss or damage may be made;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 8.1.2 the maximum liability of [each of] the Founder[s] in respect of the aggregate of all Claims shall not exceed [fifty thousand Pounds Sterling (£50,000).]
- 8.2 The maximum liability of the Company under this Agreement in respect of the aggregate of all Claims shall not exceed the maximum principal amount of the Facility.
- 8.3 The Warrantors shall not be liable and no Claim or Claims shall be made against them:
- 8.3.1 if the fact, omission, circumstances or occurrence giving rise to the Claim has been properly and fairly disclosed to the Trust in the Disclosure Letter;
- 8.3.2 if the matter giving rise to the Claim is provided for under the terms of this Agreement; or
- 8.3.3 if the Claim arises from any act, matter or thing done by the Founder[s] or the Company at and in accordance with the written request of the Trust.
- 8.4 To the extent that any breach of the Warranties is in the reasonable opinion of the Trust capable of remedy, the Trust shall, at its discretion, afford the Warrantors an opportunity to remedy the matter complained of within 30 Business Days of receipt of written notice from the Trust specifying the breach and requiring its remedy.

9. TERMINATION

Except for the provisions of Clauses 6 (Warranties), 7 (Limits on Liability), 20 (Announcements) and 21 (Confidentiality) this Agreement shall terminate immediately following the full repayment of the Loan and any Accrued Interest in cash or by conversion of the Loan into shares in accordance with Clause 4.

10. EVENTS OF DEFAULT

- 10.1 The following events or circumstances set out in this Clause 10 shall each constitute an Event of Default:
- 10.1.1 the Company fails to issue new Ordinary Shares to the Trust if requested by the Trust in accordance with the terms of Clause 4;
- 10.1.2 the Company fails to share Project Revenues or Equity Holdings if requested by the Trust in accordance with Clause 5;
- 10.1.3 any breach of a Warranty by any of the Warrantors, subject to the matters set out in the Disclosure Letter;
- 10.1.4 the Company is unable or admits inability to pay its debts as they fall due, suspends making payments on any of its debts or, by reason of actual or anticipated financial difficulties commences negotiations with one or more of its creditors with a view to rescheduling any of its indebtedness, provided that the operation of Clause 4.2 shall not constitute an Event of Default;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 10.1.5 a proposal is made or a nominee or supervisor is appointed for a composition in satisfaction of the debts of the Company or a scheme or voluntary arrangement of its affairs within the meaning of the relevant bankruptcy or insolvency laws, or the Company enters into any composition or voluntary arrangement for the benefit of its creditors, or proceedings are commenced in relation to the Company under any law, regulation or procedure relating to the re-construction, deferment or re-adjustment of all or substantially all of the Company's debts;
- 10.1.6 the Company takes any action, or any legal proceedings are started whether by a third party or not, for the purpose of the winding up or dissolution of the Company, other than for a solvent reconstruction or amalgamation;
- 10.1.7 the appointment of a liquidator, trustee, receiver, administrative receiver, receiver and manager, interim receiver custodian, sequestrator, administrator or similar officer, in respect of all or a substantial part of the assets of the Company;
- 10.1.8 an effective resolution being passed for the winding-up or entering into administration (whether out of court or otherwise) of the Company;
- 10.1.9 a distress, execution or other legal process being levied against all or substantially all of the assets of the Company, and not being discharged or paid out in full within ten (10) Business Days of the commencement of each process;
- 10.1.10 the occurrence in respect of the Company of any event in any jurisdiction to which it is subject having an effect similar to that of any of the events referred to in Clauses 10.1.1 to 10.1.9 above;
- 10.1.11 the Company ceases or threatens to cease to carry on all or a substantial part of its business or operations necessary for the completion of its obligations under this Agreement;
- 10.1.12 the Company undergoes a Change of Control, the consequences of which, in the reasonable opinion of the Trust, would be incompatible with or have an adverse effect, (i) on the Trust's charitable objectives (ii) the ability of the Company to comply with its obligations under this Agreement;
- 10.1.13 during the term of the Research, the Principal Investigator ceases to be involved with the Research, ceases to be employed by or provide services to the Company, or is prevented through illness or injury from promptly fulfilling his obligations in respect of the Research, and in the reasonable opinion of the Trust such event will jeopardise the Research or its progress;
- 10.1.14 the Project Advisory Group recommends to the Trust's Technology Transfer Division that the Trust terminates the Agreement due to a serious failure in the progress, management or conduct of the Research (including but not limited to a finding that the Research will be unable to achieve the next Milestone within a reasonable time

CONFIDENTIAL. SUBJECT TO CONTRACT.

period after the date specified in Schedule 7) or due to a major external scientific, technical or commercial barrier which the Project Advisory Group considers will mean that the Research is unlikely to succeed in its objectives, or

10.1.15 the Company fails to comply with any of the Conditions.

10.2 On the occurrence of an Event of Default the Trust may in its absolute discretion serve written notice on the Company and the Loan and Accrued Interest shall then become immediately due and payable provided that, in its absolute discretion, the Trust may by notice in writing to the Company waive its rights pursuant to this Clause 10.2.

11. OBLIGATIONS OF THE COMPANY AND THE FOUNDER[S]

11.1 The Founder[s] agree[s] to exercise all [his][their] rights and powers as a member of the Company and under this Agreement to procure (so far as [he/they] [is/are] able) that the Company shall not do any of the following (save as provided in this Agreement) and [he/they] shall not pursue any of the following in relation to the Company without the prior written consent of the Trust:

11.1.1 any amendment to its Memorandum of Association or Articles of Association;

11.1.2 the appointment and removal of the Auditors or other professional advisers;

11.1.3 the adoption of the Audited Accounts, or the annual accounts if the Company's accounts are not required to be audited;

11.1.4 any change to the accounting reference date or accounting policies;

11.1.5 any disposal or licensing of any Business IPRs;

11.1.6 any change in the share capital or the creation, allotment or issue of any shares or of any other security or the grant of any option or rights to subscribe for or to convert any instrument into such shares or securities, save for options to acquire Ordinary Shares granted under any employee share scheme pursuant to Clause 11.7 and the issue of Ordinary Shares to the Trust under Clause 4;

11.1.7 any variation of the rights attaching to any class of shares including the rights, preferences and privileges of the Ordinary Shares including any dis-application of pre-emption rights and anti-dilution protection; and

11.1.8 any payment of dividends on any class of shares.

11.2 Following receipt of a written demand from the Trust pursuant to Clause 4.1.2.1, the Company shall provide a budget to the Trust setting out its anticipated Gross Revenues and Operating Costs for the next twelve months. Following approval of the budget by the Trust, during any period where the Company is repaying the Loan to the Trust in accordance with

CONFIDENTIAL. SUBJECT TO CONTRACT.

Clause 4.4.1, any material change to the budget will require the prior written consent of the Trust.

- 11.3 The Company undertakes to the Trust so far as it lawfully can that the Company shall not and shall procure that none of its subsidiaries shall undertake any of the matters set out in Clause 11.1 without the prior written consent of the Trust. Each of the Parties expressly agrees with each of the others that any restriction imposed by law on the Company's ability to give such undertaking in respect of any matter referred to in Clause 11.1 shall not affect such undertaking as between the other Parties or any other undertaking to which such restriction does not apply.
- 11.4 The Company shall prepare and submit to the Trust Audited Accounts (if it is legally required to prepare audited accounts) and otherwise the annual accounts for the previous financial year (together with any management letters relating to them) as soon as they are available and in any event, within 120 days of the end of each financial year. The Company shall also provide additional financial or corporate information relating to the Company (including without limitation details of shareholdings, management accounts and minutes of board meetings) to the Trust upon reasonable written request.
- 11.5 The Company shall not use the "Wellcome Trust" name or logo except with the prior written consent of the Trust and in the manner approved by the Trust.
- 11.6 The Company shall be responsible for the management, monitoring and control of all research work undertaken by it. This shall include, as appropriate, the requirements of all applicable laws and regulatory authorities governing the use of radioactive isotopes, animals, pathogenic organisms genetically modified organisms, toxic and hazardous substances, research on human subjects and human embryos, and include appropriate ethical approvals and consents, including for example but not limited to, such approvals and consents for obtaining tissues and other human samples.
- 11.7 The Board shall be permitted to grant options to subscribe for Ordinary Shares in the Company to directors and employees of the Company provided that the grant of options to subscribe for Ordinary Shares in the Company representing in excess of ten per cent (10%) of the issued share capital of the Company (excluding any potential conversion of the Loan pursuant to this Agreement) shall require the prior written consent of the Trust.

12. **PROJECT MANAGEMENT**

THE RESEARCH STEERING GROUP³

- 12.1 The Company shall establish a Research Steering Group ("**RSG**") to oversee the Research, which shall have authority delegated to it from the Board of the Company to:
- a) monitor the performance and technical content of the Research;

³ Unless otherwise agreed with the Trust that such a group is not necessary

CONFIDENTIAL. SUBJECT TO CONTRACT.

- b) assess the ongoing results of the Research and what has been learnt and agree future Research;
- c) critically assess the results of the Research;
- d) identify and address any weaknesses or delays in the Research;
- e) co-ordinate internal and outsourced components of the Research;
- f) approve all public disclosures relating to the Research, including presentations, posters and papers (provided that the contribution of the Trust is acknowledged in all such publications and quoting the Award reference number);
- g) identify new inventions arising out of the Research and make recommendations for IP strategy, including patent filing and prosecution strategy and assessment of freedom to operate issues;
- h) develop a translation and commercialisation strategy, including reviewing the terms of any agreements into which the Company proposes to enter in relation to the translation and commercialisation of the Project IPRs;
- i) modify or authorise modifications to the implementation of the Research (including the implementation of the Research objectives) as necessary from time to time provided always that the RSG shall have no power to alter the fundamental scope or objectives of the Research which power is reserved to the Parties subject to compliance with the Conditions;
- j) operate as the key forum through which the Trust shall be informed as to the progress of the Research and through which the Trust shall liaise with the Company concerning the conduct of the Research, including preparing an annual report for the Trust on progress; and
- k) determine when and whether each of the research phases, Milestones or targets of the Project have been achieved,

provided that the RSG shall have no right to amend or vary the terms of this Agreement.

12.2 The RSG shall be established and run by the Parties as follows:

- a) The RSG shall be comprised of the following persons ("**Members**"):
 - i) the Principal Investigator(s);
 - ii) the Chief Scientific Officer of the Company;
 - iii) at least one independent industry adviser with experience that is relevant to the Research;
 - iv) representative(s) from any key outsourcing suppliers involved in the Research (if any); and

CONFIDENTIAL. SUBJECT TO CONTRACT.

- v) two representatives or nominees of the Trust's Technology Transfer Division (at the Trust's option).
 - b) The Trust shall have the option to appoint up to two Members, remove any Member appointed by it and to appoint any person to fill a vacancy arising from the removal or retirement of such Member. In the event that the Trust does not appoint such a Member, the Trust shall have the right to receive all papers that a Member would be entitled to receive.
 - c) The Company and the Trust shall jointly agree the identity of the other Members. The costs and expenses of the independent industry adviser(s) shall be met by the Company out of the Loan.
 - d) The Principal Investigator shall be the chairperson ("**Chair**") of the RSG and shall be responsible for organising meetings of the RSG, including preparing papers prior to meetings and ensuring minutes of meetings are produced. All papers and minutes shall be circulated to each Member in a timely manner. Except in exceptional circumstances (when such Member may nominate another person as its alternate), the Principal Investigator shall attend all RSG meetings.
 - e) The quorum for RSG meetings shall be [three (3)] Members including at least one of the independent industry adviser(s), a Trust Member and the Principal Investigator. Decisions of the RSG shall be made by majority agreement of the persons present. The Chair shall not have a casting vote. If the RSG is unable to reach agreement on a decision, the decision shall be escalated to [Director of Technology Transfer at the Trust] and [Chief Executive Officer of the Company] for resolution.
- 12.3 Meetings of the RSG shall be convened by the Chair at least once every two (2) months (or less frequently with the consent of the Trust) during the Research, on not less than fourteen (14) days' written notice (to be accompanied by an agenda for the meeting). Following the end of the Research, the RSG shall meet within thirty (30) days to discuss and report on the outcomes of the Research.
- 12.4 Any or all Members may, with the prior permission of the Chair, attend a meeting of the RSG by telephone or other electronic means rather than in person, provided that all Members attending the meeting can hear and be heard for all parts of the meeting.
- 12.5 The RSG shall have power to invite persons whose special skills or influence might advance the Research to attend and address meetings of the RSG. Such persons shall not be Members of the RSG and shall not have a right to participate in its decision-making process. The Chair shall ensure that any such invitees sign confidentiality agreements in a form acceptable to all parties.
- 12.6 The Company shall upon request make available to the Trust and/or the RSG copies of all records generated in connection with the Research.

CONFIDENTIAL. SUBJECT TO CONTRACT.

12.7 The Company shall appoint a project manager from its employees who shall be responsible on a day-to-day basis for co-ordinating the internal and external components of the Research.

13. THIRD PARTY COLLABORATIONS AND SUBCONTRACTING

13.1 Where the RSG agrees that a part of the Project shall be conducted by a third party collaborator or sub-contractor, then the Company shall ensure that such collaboration or sub-contract shall be on the following terms

13.1.1 That the third party shall not have any rights to any results emerging from such work, and all such results shall as between the parties and the third party be deemed to be Project IPRs and owned in accordance with the terms of this Agreement;

13.1.2 That the third party shall be under obligations of confidence concerning such results on terms the same as those set out under this Agreement;

13.1.3 That the third party shall keep detailed records including scientific notebooks of all of its activities and upon request shall make available copies to the Trust;

13.1.4 That the third party will upon reasonable request make available its employees for discussion with the Project Advisory Group described in clause 14 below, and

13.1.5 That the terms of such sub-contract or collaboration shall be consistent with the milestone nature of the award and the termination provisions of this Agreement.

14. PROJECT ADVISORY GROUP

14.1 The Trust may appoint a Project Advisory Group, made up of a small team of independent experts and observers from the Trust's Technology Transfer Division. The Project Advisory Group shall have reasonable access during normal working hours and at mutually agreed times to visit the premises where the Project is being conducted to consult informally with the Company's researchers, consultants or contractors working on the Research, to evaluate progress, performance and key issues and to report back to the Trust and the RSG on their findings.

14.2 The Project Advisory Group may recommend that the Trust terminates the Research in accordance with Clause 10.1.14 due to a serious failure in the progress, management or conduct of the Research (including but not limited to a finding that the Research will be unable to achieve the next Milestone within a reasonable time period after the date specified in Schedule 3), or due to a major external scientific, technical or commercial barrier which the Project Advisory Group considers will mean that the Research is unlikely to succeed in its objectives

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 14.3 If the Project Advisory Group makes such a recommendation pursuant to Clause 14.2, the Trust will, at its sole discretion, allow the Company a reasonable period of time to take corrective action to address any failings identified by the Project Advisory Group.

15. REPORTING AND NOTIFICATION OF PROJECT INVENTIONS

The Company shall procure that the Principal Investigator monitors the Research for material that may be the subject of Project Inventions and shall promptly notify the RSG of any such Project Invention. Without prejudice thereto, the Company shall report on the progress of the Research to the RSG each quarter, or from time to time as the RSG may reasonably request.

16. UNEXPLOITED INTELLECTUAL PROPERTY

- 16.1 In the event that any Project IPRs remain unexploited or not further developed by the Company and/or its licensees in any country or in respect of any indication within five Years following completion of the Research Programme, the Trust shall have the option in its sole discretion by giving written notice to the Company to take responsibility on behalf of the Company for the commercialisation and exploitation of such Project IPRs in that country or respect of that indication as the case may be, which includes discretion to make any and all decisions (in consultation with the RSG) regarding the negotiation, acceptance and conclusion of terms for any agreement regarding the commercial development and exploitation of such unexploited Project IPRs (including development and exploitation by way of licence, sale, assignment, materials transfer or other transfer of rights, as well as any transaction which involves placing such unexploited Project IPRs into a separate corporate vehicle).

- 16.2 In the event that the Trust exercises its right to exploit on behalf of the Company under Clause 16.1 above, the Company will license or assign the Project IPRs to the Trust or its nominee as required for the Trust to exploit such rights. The Company accepts that, in order to exploit the Project IPRs, it may be necessary or useful to grant a licence to the Background IPRs to the extent that it is required to exploit the Project IPRs. Any such licence grant shall be non-exclusive and free of charge.

- 16.3 In the event that the Trust exercises its right to exploit on behalf of the Company under Clause 16.1 above, the Company agrees that it shall pass to the Trust immediately any or all exploitation opportunities that it becomes aware of from time to time in connection with the Project IPRs. The Company further undertakes that it shall not engage in any activities (including in relation to the Background IPRs) that could reasonably lead to the loss of an exploitation opportunity without the prior written consent of the Trust.

- 16.4 In the event that the Trust exercises its right to exploit under Clause 16.1 above, the Trust shall share Project Revenues and Equity Holdings received in respect of exploitation of the Project IPRs in accordance with the percentages set out at Clause 5.2 after reimbursement of Trust Direct Costs.

17. FURTHER FUNDING

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 17.1 The Founder[s] and the Company undertake to procure that if the Company is raising investment (the “**Further Investment**”) by way of a subscription for shares (or any instrument convertible into shares) the Trust (or any Affiliate of the Trust nominated by the Trust) shall be given the opportunity (but not an obligation) to subscribe for the same class of shares (or the same instrument convertible into shares) in the Company at the same price per share as other investors in an amount up to a maximum of 10 per cent of the fully diluted equity of the Company. In such circumstances, the Company shall, as soon as they are made available for other potential investors, provide the Trust with a copy of an up to date business plan, the most recent management accounts and any other information provided by the Company to other potential investors or as may reasonably be requested by the Trust.
- 17.2 The Company shall procure that if the Trust converts the Loan into Ordinary Shares pursuant to Clause 4 or if the Trust participates in any Further Investment, the following terms shall apply:
- 17.2.1 the Trust shall for as long as it holds at least five per cent (5%) of the total issued share capital of the Company from time to time, be entitled to appoint a director to the Board or, if at any time it decides not to exercise such a right, to appoint an Observer to the Board. The Observer shall be entitled to receive notice of meetings, copies of the minutes of meetings and copies of all other papers circulated to the Board and any sub-committees as if he were a director;
- 17.2.2 the Trust shall be a party to a subscription and shareholders agreement which will be entered into by the major investors in the Company and which will include a standard list of matters which will require the prior approval of the Trust before being undertaken by the Company and also a comprehensive list of financial and other information which must be provided by the Company to the Trust. The Company will provide usual representations and warranties to the Trust on its subscription for shares as part of any Further Investment which representations and warranties shall be at least as restrictive as those set out in Schedule 4;
- 17.2.3 the Articles of Association of the Company will include standard tag along and co-sale rights; and
- 17.2.4 the Trust will be entitled to standard inspection and visitation rights.
- 17.3 Without prejudice to clause 17.1 above, the Company hereby grants to the Trust a first option, during the 12-month period following completion of the Research Programme, to consider funding any further development of the Project IPRs. Any such further funding requirements shall be notified to the Trust, and the Trust shall within ninety (90) days of such notification indicate to the Company whether the Trust wishes to so further fund (in whole or in part), subject to the proper Trust funding application and review process being carried out. If the Trust elects to exercise the option, then the Parties shall negotiate in good faith the terms of such further funding. If the Trust does not so elect, then the option shall lapse.

18. **WAIVER**

CONFIDENTIAL. SUBJECT TO CONTRACT.

No Party shall be deemed to have waived any of its rights or remedies under this Agreement unless the waiver is expressly made in writing and signed by a duly authorised representative of that Party. In particular, no delay or failure of any Party in exercising or enforcing any of its rights or remedies under this Agreement shall operate as a waiver of those rights or remedies nor shall any single or partial exercise or enforcement of any right or remedy by any Party preclude or impair any other exercise or enforcement of that right or remedy by that Party.

19. **ENTIRE AGREEMENT/VARIATIONS**

- 19.1 This Agreement, together with the Application for a Seeding Drug Discovery Award made by the Company to the Trust on ● 200● and any agreement entered into pursuant to such agreements constitutes the entire agreement and understanding between the Parties relating to the subject matter hereof and together they supersede and replace all prior drafts, previous understandings, arrangements, representations or agreements, whether in writing or oral, between the Parties relating to the subject matter of this Agreement.
- 19.2 No variation, amendments, modification or supplement to this Agreement shall be valid unless and until it is made in writing and signed by a duly authorised representative of each Party.

20. **ANNOUNCEMENTS**

- 20.1 Save as required by law or any competent regulatory authority no announcement concerning this Agreement or its subject matter shall be made by any of the Parties without the prior approval of the Trust.
- 20.2 The Trust's contribution must be acknowledged in all scientific publications, quoting the Award reference number.

21. **CONFIDENTIALITY**

- 21.1 The Parties shall keep confidential and ensure that their respective Connected Persons, and their respective officers, employees, agents and professional and other advisers shall keep confidential any information listed in Schedule 8 or otherwise:
- 21.1.1 relating to the customers, business, assets or affairs of the Company;
- 21.1.2 relating to the customers, business, assets or affairs of the other Parties; or
- 21.1.3 which relates to the contents of this Agreement or any agreement or arrangement entered into pursuant to this Agreement (the "**Confidential Information**").
- 21.2 Save as set out below, no Party may use for its own business purposes or disclose to any third party any Confidential Information of any other Party without the prior consent of the Party to whom the Confidential Information relates. This Clause does not apply to:

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 21.2.1 information which is or becomes publicly available (otherwise than as a result of a breach of this Agreement or any other agreement between the parties); or
 - 21.2.2 information which is independently developed by the relevant Party or acquired from a third Party, to the extent that it is acquired with the right to disclose it;
 - 21.2.3 information which was lawfully in the possession of the relevant Party prior to or on the Effective Date, free of any restriction on disclosure as can be shown by that Party's written records or other reasonable evidence;
 - 21.2.4 the disclosure of information to the extent required to be disclosed by law, including any requirements for disclosure under the Freedom of Information Act 2000 or any court of competent jurisdiction, any governmental official, any tax or regulatory authority (including any Recognised Investment Exchange and the Panel on Takeovers and Mergers) or any binding judgement, order or requirement of any other competent authority [Where such disclosure of information is required under the Freedom of Information Act 2000 from a Party designated as a public authority under that Act and such information relates to another Party, the public authority shall notify that Party within five (5) Business Days of receiving an information request that such a request has been made and the details thereof. The public authority shall allow five (5) Business Days to consult with and, to the extent permitted by law, take into account any representations made by the Party concerned before such information is disclosed to the requestor and shall on request provide an update of the status of the public authority's response and the information which it is intending to disclose];
 - 21.2.5 the disclosure to a Party's professional advisers or to the Trust's Project Advisory Group of information reasonably required to be disclosed for purposes relating to this Agreement;
 - 21.2.6 any announcement made, or information provided in relation to the Company with the approval of the Trust in accordance with Clause 20; and
 - 21.2.7 the disclosure of information by the Trust for the purposes of publishing summary details of awards made by the Trust including the name of the Company, the name of the Founder[s], the name of the Principal Investigator, the title of the project and the amount of the award.
- 21.3 Each Party shall inform any officer, employee or agent or any professional or other adviser advising it in relation to matters relating to this Agreement, or to whom it provides Confidential Information, that such information is confidential and shall instruct them:
- 21.3.1 to keep it confidential; and

CONFIDENTIAL. SUBJECT TO CONTRACT.

21.3.2 not to disclose it to any third party (other than those persons to whom it has already been or may be disclosed in accordance with the terms of this Agreement),

provided that the disclosing Party shall remain responsible for any breach of this Clause 21 by the person to whom that Confidential Information is disclosed.

21.4 Without prejudice to any other rights or remedies which a Party may have, the Parties acknowledge and agree that damages would not be an adequate remedy for any breach of this Clause and the remedies of injunction, specific performance and other equitable relief are appropriate for any threatened or actual breach of any such provision.

22. NOTICES

22.1 Any notice to be given pursuant to this Agreement shall be in writing in the English language and shall be delivered by overnight courier, by registered, recorded delivery or certified mail (postage prepaid) or by facsimile confirmed by registered, recorded delivery or certified mail (postage prepaid) to the address or facsimile number of the recipient Party set out below or such other address or facsimile number as a Party may from time to time designate by written notice to the other Parties. Any notice by facsimile shall be confirmed by the sender sending a confirmatory copy of the notice by registered, recorded delivery or certified mail (postage prepaid).

Address of Company

[Address]
[Address]
[Address]

Fax No: [00000000000]

for the attention of: [Name]

Address of Founder[s]

[Address]
[Address]
[Address]

Fax No: [00000000000]

for the attention of: [Name]

Address of the Trust

Technology Transfer Division
The Wellcome Trust Limited,
215 Euston Road
London NW1 2BE

Fax No: +44 (0) 20 7611 8857

for the attention of: The Awards Officer

CONFIDENTIAL. SUBJECT TO CONTRACT.

with a copy to: [Name of Business Analyst]

22.2 Any notice given pursuant to this Clause 22 shall be deemed to have been received:

22.2.1 in the case of delivery by courier or sending by certified mail, on the day of receipt, provided receipt occurs on a Business Day of the recipient Party or otherwise on the next following Business Day of the recipient; or

22.2.2 in the case of facsimile, on acknowledgement by the recipient facsimile receiving equipment on a Business Day if the acknowledgement occurs before 5:00 pm local time of the recipient Party and in any other case on the following Business Day.

22.3 Any notice that is required in this Agreement to be given in writing shall include notices by fax or post but shall not include any notice by e-mail.

23. **ASSIGNMENT**

No Party shall without the prior written consent of the other Parties assign, transfer, convey or declare a trust over this Agreement or make any other disposition (whether in whole or in part) or any of its rights and obligations hereunder to any third party.

24. **SEVERANCE OF TERMS**

24.1 If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable in any jurisdiction for any reason (including both by reason of the provisions of any legislation and also by reason of any court or competent authority which either has jurisdiction over this Agreement or has jurisdiction over any of the Parties):

24.1.1 in the case of the illegality, invalidity or un-enforceability of the whole of this Agreement it shall terminate only in relation to the jurisdiction in question; or

24.1.2 in the case of the illegality, invalidity or un-enforceability of part of this Agreement that part shall be severed from this Agreement in the jurisdiction in question and that illegality, invalidity or un-enforceability shall not in any way whatsoever prejudice or affect the remaining parts of this Agreement, which shall continue in full force and effect.

24.2 If in the reasonable opinion of any Party any severance under this Clause 24 materially affects the commercial basis of this Agreement, the Parties shall discuss, in good faith, ways to eliminate the material effect.

25. **COSTS**

Each Party shall bear its own legal costs, legal fees and other expenses incurred in the preparation and execution of this Agreement.

26. **FURTHER ASSURANCES**

CONFIDENTIAL. SUBJECT TO CONTRACT.

Each Party shall perform such acts and execute such documents as may be reasonably required for securing to or vesting in another Party the rights agreed to be granted to it under or pursuant to this Agreement.

27. **GENERAL**

27.1 If any provisions of the Memorandum or Articles of the Company at any time conflict with any of the provisions of this Agreement, the provisions of this Agreement shall prevail.

27.2 Nothing in this Agreement shall be taken to constitute a partnership between the Parties. Except as specifically provided in this Agreement, none of the Parties shall by reason of this Agreement be empowered to act as agent for any other party nor to pledge the credit of any other party nor shall any Party be held liable for or incur liability in respect of the acts or defaults of any other Party to this Agreement.

27.3 This Agreement may be executed in any number of counterparts and by the Parties on separate counterparts, but shall not be effective until each Party has executed at least one counterpart. Each counterpart shall constitute an original of this Agreement, but all the counterparts shall together constitute one and the same instrument.

27.4 A person who is not a Party has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy the benefit of any term of this Agreement.

28. **GOVERNING LAW**

This Agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this Agreement or its formation) shall be governed by and construed in accordance with the laws of England. The Parties irrevocably submit to the exclusive jurisdiction of the Courts of England.

IN WITNESS of which this Agreement has been signed as follows:

Signed for and on behalf of)
THE WELLCOME TRUST)
LIMITED as trustee of)
The Wellcome Trust)
by its authorised signatory)

.....
Authorised Signatory

Signed for and on behalf of)
THE WELLCOME TRUST)
LIMITED as trustee of)
The Wellcome Trust)
by its authorised signatory)

.....
Authorised Signatory

Signed for and on behalf of)
[COMPANY])
LIMITED)

.....
Director

.....
Director/Secretary

Signed by)
[FOUNDER[S]])

.....

CONFIDENTIAL.

SCHEDULE 1

Notice of Drawdown

[Company] Limited
[Address]
[Address]
[Address]

[Individual/Founder]
[Address]
[Address]
[Address]

The Awards Officer
Technology Transfer Division
The Wellcome Trust Limited
The Wellcome Building
215 Euston Road
London NW1 2BE

[Date]

Dear Sirs

The Funding Agreement made on [] 2005 between [Company] and The Wellcome Trust Limited (the "Loan Agreement")

We hereby give you irrevocable notice that, pursuant to Clause [2.5] of the Loan Agreement we wish to borrow • Pounds Sterling (£•) of the Facility Amount upon the terms and subject to the conditions of the Loan Agreement.

We confirm that each condition specified in Clause [2.9] is satisfied on the date of the proposed drawdown.

Terms and expressions defined in the Loan Agreement shall have the same meanings in this Letter.

Yours faithfully

.....
For and on behalf of
[Company]

SCHEDULE 2

Milestone Certification and Drawdown Notice

[Company] Limited
[Address]

[Individual/Founder]
[Address]

The Awards Officer
Technology Transfer Division
The Wellcome Trust Limited
215 Euston Road
London NW1 2BE

[Date]

Dear Sirs

The Funding Agreement made on [] 2005 between [Company] and The Wellcome Trust Limited (the "Loan Agreement")

We refer to Milestone [One][Two] as described in the Loan Agreement and hereby confirm the completion of the achievement of such Milestone. A report detailing achievement of Milestone [One][Two] is attached to this letter. Please confirm that Milestone [One][Two] has been achieved to your reasonable satisfaction and that we may proceed to drawdown £[•] in respect of the [Second][Third] tranche of the Facility.

Subject to receipt of your confirmation that we may proceed to drawdown the Facility, we hereby give you irrevocable notice that, pursuant to the Loan Agreement we wish to borrow Pounds Sterling £[insert amount of Advance] of the Facility Amount upon the terms and subject to the conditions of the Loan Agreement and, in accordance with Clause [2.6] of the Loan Agreement.

We confirm that each condition specified in Clause [2.9] is satisfied on the date of the proposed drawdown.

Terms and expressions defined in the Loan Agreement shall have the same meanings in this Letter.

Yours faithfully

.....
For and on behalf of
[Company]

SCHEDULE 3

Part I Details of [name of Company]

- (1) Company Number: []
- (2) Date and Place of Incorporation: []
- (3) Share Capital:
 - (i) Authorised: []
 - (ii) Issued: []
- (4) Registered Holder: []
- (5) Registered Office: []
- (6) Director: []
- (7) Secretary: []
- (8) Accounting Reference Date: []

SCHEDULE 4

Warranties

1. THE COMPANY

The details of the Company set out in Schedule 3 are correct and accurate.

2. CAPACITY

2.1. The Company has full power and authority to enter into and perform this Agreement, and this Agreement constitutes a binding obligation on the Company in accordance with its terms.

2.2. The execution and performance by the Company of its obligations under this Agreement will not:

- (a) result in a breach of any provision of its Memorandum of Association or Articles; or
- (b) constitute a default under any agreement, instrument or arrangement, whether binding or not, to which the Company is a party, or any order, judgement or decree of any court or governmental agency to which the Company or the Founder[s] are a party or by which any of them are bound.

3. SHARES AND LOAN CAPITAL

3.1. The person[s] listed in Schedule 3 as the registered shareholder [is][are] the [sole] beneficial owner[s] of the number of shares in the Company set out opposite [his][their] name in Schedule 3 which constitutes all the issued shares of the Company.

3.2. There is no conditional or unconditional agreement or commitment outstanding that calls for the allotment, issue, transfer or conversion of any share of the Company other than as provided in this Agreement.

3.3. There is no option, right to acquire, pledge, lien, mortgage or charge or other form of security or encumbrance or equity on, over or affecting any shares in the Company and there is no conditional or unconditional agreement or commitment to give or create any and no claim has been made by any person to be entitled to any other than as provided in this Agreement and any relevant statutory provisions.

3.4. The Company does not have and has never had any beneficial interest in or legal title to any equity capital or loan capital in any other person.

3.5. The Company does not act or carry on business in partnership with any other person, nor is the Company a member (otherwise than through the holding of share capital) of any corporate or unincorporated body, undertaking or association.

CONFIDENTIAL. SUBJECT TO CONTRACT.

- 3.6. The issue of the Shares in accordance with this Agreement will comply with all applicable laws and with all other agreements by which the Company is bound. All of the shares when issued in accordance with this Agreement will be validly issued and fully paid.
- 3.7. The existing Articles set out all the rights and privileges which are applicable to the Company and neither the Company nor the director nor the existing shareholder[s] [has/have] entered into any agreement, understanding or arrangement amending, modifying or supplementing any of the same.

4. INFORMATION AND ACCOUNTS

- 4.1. All facts and information concerning the Company reasonably believed by the Warrantors to be material for disclosure to the Trust in connection with the grant of the Facility pursuant to this Agreement have been fairly disclosed in the Business Plan or in the Disclosure Letter.
- 4.2. The Warrantors have carefully reviewed the Business Plan and:
 - (a) the Business Plan has been prepared with reasonable skill, diligence and care;
 - (b) all factual information contained in the Business Plan was when given and remains true and accurate and not (whether by omission or otherwise) misleading;
 - (c) all statements of opinion, forecasts, projections and budgets contained or referred to in the Business Plan:
 - (i) have been honestly and reasonably made;
 - (ii) have been properly prepared on bases and assumptions which are honestly considered by the Warrantors, after careful enquiry, to be fair and reasonable; and
 - (iii) are fair and reasonable in the circumstances,and neither the opinions, forecasts and projections, nor the assumptions on which they were based are misleading in any material respect in the light of any events or circumstances that have arisen since the preparation of the Business Plan.

5. THE AUDITED ACCOUNTS

- 5.1. A true, complete and fair copy of the Audited Accounts is annexed to the Disclosure Letter.
- 5.2. The Audited Accounts were prepared under the historic cost convention and complied with, and were prepared in accordance with, all applicable accounting requirements, and have been carefully prepared on a basis consistent with generally accepted accounting practices and policies in the United Kingdom.

CONFIDENTIAL. SUBJECT TO CONTRACT.

5.3 The Audited Accounts:

- (a) give a true and fair view of the assets and liabilities of the Company as at the Accounts Date and of its profits for the financial period ended on the Accounts Date;
- (b) fully disclose all the assets of the Company as at the Accounts Date;
- (c) make provision for, reserve for or disclose, as appropriate, all liabilities, whether actual, contingent, unquantified or disputed, all capital commitments, whether actual or contingent, and all bad or doubtful debts of the Company as at the Accounts Date in accordance with all relevant accounting requirements, and
- (d) make provision for or reserve for deferred taxation in accordance with all applicable accounting requirements.

6. **THE MANAGEMENT ACCOUNTS**

- 6.1. The Management Accounts have been prepared honestly and diligently and fairly reflect the financial position of the Company as at •.
- 6.2. So far as the Company is aware, there has been no material change in the financial position of the Company that would affect the Management Accounts since •.
- 6.3. The Management Accounts have been reviewed and approved by the Board.

7. **POSITION SINCE THE ACCOUNTS DATE**

Since the Accounts Date:

- (a) no dividend or other distribution (within the meaning of that expression as contained in section 209 or 210 or 418 of the Income and Corporation Taxes Act 1988) has been declared, paid or made by the Company;
- (b) the Company has carried on its business in the ordinary and usual course without any interruption in its nature, scope or manner and so as to maintain the same as a going concern;
- (c) the Company has not written off any debts, no debt has been released by the Company on terms that the debtor pays less than the book value of its debt, and no debt owing to the Company has proved to any extent to be irrecoverable;
- (d) the Company has not entered into any contract involving expenditure on capital account or the purchase of any capital equipment or other items of a capital nature;
- (e) the business of the Company has not been materially or adversely affected by the loss of any customer;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- (f) there has been no material adverse change in the financial position or trading prospects or turnover of the Company and, so far as the Warrantors are aware, no event, fact or matter has occurred or is likely to occur which will or is likely to give rise to any such change;
- (g) no contract or commitment (whether in respect of capital expenditure or otherwise) has been entered into by the Company on terms which will allow for less than full recovery of costs, overheads and profit or which is of a long term or unusual nature, or which involves an obligation of a material nature or magnitude; and for this purpose a long term contract or commitment is one which will not be performed in accordance with its terms within three months after the date it was entered into or undertaken or which is incapable of termination by the Company on three months' notice or less;
- (h) the Company has not acquired or disposed of or agreed to acquire or dispose of any business or any asset or assumed or acquired any liability (including any contingent liability) or made any payment otherwise than in the ordinary course of business and at arm's length;
- (i) the Company has not disposed of or agreed to dispose of any asset for a consideration payable by instalments where any instalment remains unpaid;
- (j) so far as the Warrantors are aware, all cash and payments of any kind received by the Company have been credited to its accounts with its bankers;
- (k) so far as the Warrantors are aware, the Company has paid its creditors in accordance with the same policy as that adopted throughout the financial period ended on the Accounts Date;
- (l) so far as the Warrantors are aware none of the assets of the Company has been diminished by the wrongful act of any person; and
- (m) so far as the Warrantors are aware the Company has not by doing or omitting to do anything prejudiced its goodwill.

8. LICENCES AND CONSENTS

The Company has obtained all governmental and regulatory licences, permissions, authorisations and consents required to own and operate its assets and for the proper carrying on of its business which are in full force and effect and the Company is not in breach of any of the terms and conditions attached to any of them.

9. ASSETS

The Company owns all the assets used in the operation of its business and which are material to the operation of its business. None of such assets are subject to any Encumbrance.

10. DEBTS

The Company does not owe any sums other than trade debts incurred in the

ordinary course of business.

11. CONFIDENTIAL INFORMATION

- 11.1. The Company does not use any processes or business methods, and is not engaged in any activities, which involve the misuse or alleged misuse of any confidential information belonging to any third party.
- 11.2. The Warrantors are not aware of any actual or alleged misuse by any person of any of the Company's confidential information (including customer lists which are maintained by or on behalf of the Company in any format or medium).
- 11.3. The Company has not disclosed to any person any of its confidential information except (i) to its professional advisers; or (ii) where such disclosure was properly made in the normal course of the Company business and was made subject to a written agreement under which the recipient is obliged to maintain the confidentiality of such confidential information and is restrained from further disclosing or using it other than for the purposes for which it was disclosed by the Company.

12. INTELLECTUAL PROPERTY RIGHTS

- 12.1. Save in respect of the Licensed-In IPRs, the Company is the sole legal and beneficial owner and, where registered, the sole registered proprietor of all the Business IPRs free from all Encumbrances.
- 12.2. To the best of the knowledge, information and belief of the Warrantors, the Business IPRs are valid and enforceable and not subject to any pending or threatened claims, challenges or proceedings.
- 12.3. So far as the Warrantors are aware, no third party has made unauthorised use of any Business IPRs nor threatened to do so.
- 12.4. The Company has taken all steps and made all payments which are required to prosecute, maintain and renew all Business IPRs within the required timescales.
- 12.5. No licensee of any Business IPRs is in breach of the relevant agreement, and there are no actual or pending disputes in relation to such agreements.
- 12.6. To the best of the knowledge, information and belief of the Warrantors, all agreements relating to Licensed-In IPR are valid and in force. No notice has been given by any relevant party to terminate any of them. The Company and all counterparties have complied with their respective obligations, and no disputes are pending or threatened in respect of any of them.
- 12.7. To the best of the knowledge, information and belief of the Warrantors, none of the activities of the Company infringe, or have been alleged to infringe, the IPRs of any third party.

CONFIDENTIAL. SUBJECT TO CONTRACT.

12.8. The Company carries on its business under its corporate name and no other.

13. DATA PROTECTION

13.1. The Company has a current notification under the UK Data Protection Act 1998 (“**DPA**”) on terms which are appropriate to cover its current and foreseeable activities in relation to its business.

13.2. The Company has complied in all material respects with the DPA and its preceding legislation.

13.3. The Company owns all IPRs in its customer lists and databases.

13.4. No correspondence has been received from the UK Information Commissioner, or from any third party, regarding a breach or alleged breach by the Company of its obligations under the DPA, and no dispute has arisen or is threatened in relation to the same.

14. CONTRACTS WITH CONNECTED PERSONS

14.1. There are no existing contracts or engagements to which the Company is a party and in which the Founder[s] and/or any director of the Company and/or any person who is a Connected Person with any of them is interested.

14.2. The Founder[s] and/or any person who is a Connected Person with the Founder[s] [does][do] not own and [is][are] not otherwise interested in any property used in connection with the business of the Company.

14.3. The Founder[s] [is][are] not either collectively or individually or with any other person or persons, directly or indirectly, engaged in any other business and [he][they] [is][are] not concerned or interested in any way whatsoever in any other business of a similar nature to or competitive

14.4. There are no arrangements or other commitments of the Founder[s] which could affect [his][their] ability to devote [his][their] required working hours to the affairs of the Company.

15. CONTRACTS

15.1. The Company is not a party to or bound by:

- (a) any contract (including a contract otherwise wholly performed under which obligations or liabilities may arise in the future) not in the ordinary and proper course of its business;
- (b) any guarantee or contract of indemnity (whether within or outside the ordinary course of business) by virtue of which it is under an actual or contingent liability;
- (c) any power of attorney;
- (d) any contract in respect of which the liability or prospective liability of the Company is guaranteed by any person;

CONFIDENTIAL. SUBJECT TO CONTRACT.

- (e) any distributorship or agency contract; or
- (f) any joint venture, consortium, partnership or profit sharing arrangement or agreement or a member of any partnership, whether formal or informal and whether or not having a separate legal identity.

16. BORROWINGS

Except as disclosed in the accounts the Company does not have outstanding:

- (a) any borrowing or indebtedness in the nature of borrowing including any bank overdrafts, liabilities under acceptances (otherwise than in respect of normal trade bills) and acceptance credits other than borrowing or indebtedness arising in the ordinary course of business;
- (b) any guarantee indemnity or undertaking (whether or not legally binding) to procure the solvency of any person or any similar obligation.

17. LITIGATION, OFFENCES AND COMPLIANCE WITH STATUTES

- 17.1. Otherwise than as claimant in the collection of debts arising in the ordinary course of business (none of which exceed £1,000) neither the Company nor any person for whose acts or defaults the Company may be vicariously liable is claimant, defendant or otherwise a party to any litigation, arbitration or administrative proceedings which are in progress or are threatened or pending by or against or concerning the Company or any of its assets; the Company is not being prosecuted for any criminal offence and no governmental or official investigation or inquiry concerning the business or officers of the Company or any of its assets is in progress or pending and there are no circumstances which are likely to give rise to any such proceedings investigation or inquiry.
- 17.2. Neither the Company nor any of its officers, agents or employees (during the course of their duties in relation to the business of the Company) has committed or omitted to do any act or thing which is or could be in contravention of any statutory obligation or any other law of the United Kingdom or any other country giving rise to any fine, penalty, default proceedings or other liability in relation to the business or officers of the Company or any of its assets or any judgment or decision which would materially affect the financial or trading position or prospects of the Company.
- 17.3. None of the Warrantors has ever been charged with or convicted of any criminal offence other than a road traffic offence (not involving a custodial sentence, whether suspended or not).
- 17.4. The Founder[s] [has][have] never been the subject of any order under Company Directors Disqualification Act 1986 or been adjudged bankrupt or been the subject of a petition for a bankruptcy order duly presented to the court or entered into a voluntary arrangement (within the meaning given in Section 253 of the Insolvency Act 1986) or been the subject of an interim order under Section 252 of that Act. No analogous proceedings have ever been brought or threatened in respect of any of the directors of the Company and the directors of the

CONFIDENTIAL. SUBJECT TO CONTRACT.

Company are not aware of any facts or matters which they believe might give rise to any such criminal or bankruptcy proceedings.

18. TAXATION

- 18.1. The Company has no Tax liability resulting from or by reference to any income, profits or gains earned, accrued or received on or before the date hereof.
- 18.2. The Company is registered for VAT and has complied with all requirements relating to VAT and all returns, computations, notices and information which are or have been required to be made or given by the Company for any Tax purpose (i) have been made or given in all material respects within the requisite periods and on a proper basis and are up-to-date and correct and (ii) none of them is, or is likely to be, the subject of any dispute with the Inland Revenue or other Tax authority.

19. ADMINISTRATION

- 19.1. All the accounts, books, registers, ledgers and financial and other material records of whatsoever kind of the Company (including all invoices and other records required for VAT purposes) are up to date, in its possession or under its control and have been fully properly and accurately kept and compiled.
- 19.2. Every document required by the Companies Acts to be filed with the Registrar of Companies has been duly filed and compliance has been and is being made by the Company with the Companies Acts.
- 19.3. The copy of the Memorandum and Articles of Association of the Company provided to the Trust is accurate and complete in all respects, includes copies of all resolutions and documents required to be incorporated therein and fully sets out all rights attaching to each class of the share capital of the Company. The register of members and other statutory books of the Company have been properly kept and contain a true, accurate and complete record of all the matters which should be dealt with therein and no notice or allegation that any of the same is incorrect or should be rectified has been received.
- 19.4. All legal requirements in connection with the formation of the Company have been observed and all material legal requirements in connection with the conduct of the Company have been observed.
- 19.5. The Company has not at any time carried on any business other than the business carried on at the date hereof.
- 19.6. No order has been made or petition presented or resolution passed for the winding-up of the Company, no distress, execution or other process has been levied on any of its assets, it has not suspended payment and is not insolvent or unable to pay its debts within the meaning of section 123 Insolvency Act 1986, no order has been made or petition presented or resolution passed for the appointment of an administrator, no receiver has been appointed or could be appointed by any person of its business or assets or undertaking or any part thereof and there is no

CONFIDENTIAL. SUBJECT TO CONTRACT.

unfulfilled or unsatisfied judgment, arbitration award or court order or arbitration order outstanding against it and the Company is not aware of any matter which might lead to the occurrence of any such an event.

CONFIDENTIAL. SUBJECT TO CONTRACT.

SCHEDULE 5

The Application

[]

CONFIDENTIAL. SUBJECT TO CONTRACT.

SCHEDULE 6

The Research Programme

[]

SCHEDULE 7

Milestones & Conditions

SPECIFIC MILESTONES

Milestone One

The achievement of the following:

[]

It is expected that Milestone One will be achieved by [• months] from the Effective Date.

Milestone Two

The achievement of the following:

[]

It is expected that Milestone Two will be achieved by [• months] from the Effective Date.

Milestone Three

The achievement of the following:

[]

It is expected that Milestone Three will be achieved by [• months] from the Effective Date.

CONDITIONS

The satisfaction of the following throughout the duration of the Research:

1. formation and operation of the RSG in accordance with Clause 12;
2. engagement of an independent industry adviser with relevant experience;
3. timely submissions of annual reports on Research progress to the Trust;
4. co-operation with the Project Advisory Group prior to and during visits;
5. timely consultation with the Trust on patent strategy and patent prosecution;
6. timely consultation with the Trust on translation or commercialisation strategy;
7. compliance with grant conditions and any other agreements between the Company and the Trust relating to the Research; and

CONFIDENTIAL. SUBJECT TO CONTRACT.

8. filing prosecution and maintenance of Business IPRs as required for the Company to carry out the Research.

CONFIDENTIAL. SUBJECT TO CONTRACT.